Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC

Felice Giuliante, Luca Vigano', Guido Torzilli, Fabio Maria Vecchio, Luca Viganò, Simone Conci, Matteo Cescon, Cristina Fava, Paola Capelli, Antonietta D'Errico, Luca Di Tommaso, Mauro Salizzoni, Ezio David, Antonio Daniele Pinna, Alfredo Guglielmi, Lorenzo Capussotti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

40 Citazioni (Scopus)

Abstract

Background & Aims The incidence of metabolic syndrome-related hepatocellular carcinoma (MS-HCC) is increasing worldwide. High resection risks are anticipated because of underlying steatohepatitis, but long-term results are unknown. To clarify the outcomes following liver resection in patients with MS-HCC and to compare the outcomes of MS-HCC to HCV-related HCC (HCV-HCC). Methods All the consecutive patients undergoing liver resection for HCC in six high-volume HPB units between 2000 and 2012 were retrospectively considered. The patients with MS-HCC were identified and matched one-to-one with HCV-HCC patients without metabolic syndrome. Matching was based on age, cirrhosis, Child-Pugh class, portal hypertension, HCC number and diameter and liver resection extension. Results Among 1563 patients undergoing liver resection for HCC in the study period, 96 (6.1%) had MS-HCC. They were matched with 96 HCV-HCC patients. All patients were Child-Pugh class A, 22.9% had cirrhosis. Forty-one patients per group (42.7%) required major hepatectomy. The MS-HCC group had a higher prevalence of steatohepatitis (25.0% vs. 9.4%, p = 0.004). Operative mortality was 2.1% (1 MS-HCC, 3 HCV-HCC, p = 0.621). Morbidity and liver failure rates were similar between the two groups. In the multivariate analysis, cirrhosis, major hepatectomy, and MELD >8, but not steatohepatitis, impacted severe morbidity and liver failure rates. The MS-HCC group had better 5-year overall survival (65.6% vs. 61.4%, p = 0.031) and recurrence-free survival (37.0% vs. 27.5%, p = 0.077). Independent negative prognostic factors were HCV-HCC, multiple HCC, microvascular invasion, and satellite nodules. Conclusions Liver resection is safe for MS-HCC, as for HCV-HCC. Cirrhosis, but not steatohepatitis, affects short-term outcomes. MS-HCC is associated with excellent long-term outcomes, better than HCV-HCC.
Lingua originaleEnglish
pagine (da-a)93-101
Numero di pagine9
RivistaJournal of Hepatology
Volume63
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular
  • Cirrhosis
  • Female
  • Follow-Up Studies
  • HCV-related HCC
  • Hepatectomy
  • Hepatitis C, Chronic
  • Hepatocellular carcinoma
  • Hepatology
  • Humans
  • Liver Neoplasms
  • Liver failure
  • Liver surgery
  • Male
  • Metabolic Syndrome X
  • Metabolic syndrome
  • Middle Aged
  • Non-alcoholic fatty liver disease
  • Non-alcoholic steatohepatitis
  • Obesity
  • Retrospective Studies
  • Steatosis
  • Survival
  • Treatment Outcome

Fingerprint Entra nei temi di ricerca di 'Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC'. Insieme formano una fingerprint unica.

Cita questo